Quanta (QNTA) 10-Q/A 23 Nov 21 2021 Q3 Quarterly report (amended) Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 19, 2021
Cover [Abstract]
Document Type	10-Q/A
Amendment Flag	true
Amendment Description	Amendment No. 1
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-56025
Entity Registrant Name	Quanta, Inc.
Entity Central Index Key	0001691430
Entity Tax Identification Number	81-2749032
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	632 S Glenwood Pl
Entity Address, City or Town	Burbank
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91506
City Area Code	(424)
Local Phone Number	261-2568
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		214,733,156

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash	$ 22,262	$ 6,270
Accounts receivable		685
Inventories, net	73,748	19,220
Prepaid production cost	300,000
Deferred charges – related party		134,704
Total current assets	396,010	160,879
Equipment, net	187,061	200,523
Operating lease right-of-use asset, net	300,483	362,227
Deposits	16,883	16,883
Total assets	900,437	740,512
Current liabilities:
Accounts payable and accrued expenses	590,448	673,494
Advances	106,000
Notes payable (net of deferred finance charges of $53,667 and $74,817 at September 30, 2021 and December 31, 2020, respectively)	415,358	482,724
Convertible note payable (net of discount of $204,230 and $539,282 at September 30, 2021 and December 31, 2020, respectively)	2,018,564	1,074,814
Deferred revenue, license agreement	11,370	34,818
Operating lease liabilities, short-term	105,443	100,901
Lease settlement obligation	235,759	235,759
Total current liabilities	3,482,942	2,602,510
Long term liabilities
Notes payable, long term (net of deferred finance charge of $- and $32,556 at September 30, 2021 and December 31, 2020, respectively)	294,125	451,368
Operating lease liabilities, long-term	230,742	294,880
Total liabilities	4,007,809	3,348,758
Commitments and contingencies:
Mezzanine equity:
Total Mezzanine equity	1,691,331
Stockholders’ deficit:
Preferred stock, $0.001 par value; 25,000,000 shares authorized; 2,500,000 issued and outstanding	2,500	2,500
Common stock, $0.001 par value; 3,000,000,000 shares authorized; 207,604,585 and 46,756,970 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	207,608	46,757
Shares to be issued (4,875,000 and 4,875,000 as of September 30, 2021 and December 31, 2020, respectively)	4,024,412	3,641,868
Additional paid-in capital	13,998,658	10,102,805
Accumulated deficit	(22,300,233)	(16,402,176)
Total Quanta, Inc. stockholders’ deficit	(4,067,055)	(2,608,246)
Noncontrolling interest in consolidated subsidiary	(731,648)
Total stockholders’ deficit	(4,798,703)	(2,608,246)
Total liabilities, mezzanine equity, and stockholders’ deficit	900,437	740,512
Series B Preferred Stock [Member]
Mezzanine equity:
Total Mezzanine equity	1,522,198
Series C Preferred Stock [Member]
Mezzanine equity:
Total Mezzanine equity	$ 169,133

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Deferred finance charges, noncurrent	$ 53,667	$ 74,817
Convertible note payable, discount	204,230	539,282
Debt Issuance Cost, Gross, Noncurrent	$ 0	$ 32,556
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	2,500,000	2,500,000
Preferred stock, shares outstanding	2,500,000	2,500,000
Common Stock, Par or Stated Value Per Share		$ 0.001
Common Stock, Shares Authorized	3,000,000,000	3,000,000,000
Common Stock, Shares, Outstanding	207,604,585	46,756,970
Shares to be issued, shares	4,875,000	4,875,000
Series B Preferred Stock [Member]
Mezzanine equity, par value	$ 0.00001	$ 0.00001
Mezzanine equity, shares authorized	9,000	9,000
Mezzanine equity, shares issued	9,000	0
Mezzanine equity, shares outstanding	9,000	0
Series C Preferred Stock [Member]
Mezzanine equity, par value	$ 0.00001	$ 0.00001
Mezzanine equity, shares authorized	1,000	1,000
Mezzanine equity, shares issued	1,000	0
Mezzanine equity, shares outstanding	1,000	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Total revenue	$ 105,009	$ 323,700	$ 548,501	$ 998,657
Cost of goods sold	81,986	52,502	161,615	150,960
Gross profit	23,023	271,198	386,886	847,697
Operating expenses:
Research and development (includes $105,000 and $315,000 royalty to related party for the three months and nine months ended September 30, 2021, respectively, and $180,000 for the nine months ended September 30, 2020)	105,000	62,006	348,500	306,544
Selling, general, and administrative (includes $218,772 and $628,742 administrative to related party for the three months and nine months ended September 30, 2021, respectively)	912,632	1,210,363	6,598,511	4,651,018
Impairment of operating lease right of use asset		255,093		255,093
Total operating expenses	1,017,632	1,527,462	6,947,011	5,212,655
Loss from operations	(994,609)	(1,256,264)	(6,560,125)	(4,364,958)
Other income (expense):
Interest expense	(152,184)	(70,236)	(243,710)	(476,359)
Debt discount amortization	(77,777)	(116,566)	(146,472)	(395,789)
Change in fair value derivative		(181,913)		101,226
Loss on extinguishment of debt		(1,081,491)		(795,491)
Other income and expense, net	(229,961)	(1,450,206)	(390,182)	(1,566,413)
Net loss	(1,224,570)	(2,706,470)	(6,950,307)	(5,931,371)
Net loss attributable to noncontrolling interest	182,626		731,648
Net loss attributable to Quanta, Inc.	$ (1,041,944)	$ (2,706,470)	$ (6,218,659)	$ (5,931,371)
Net loss per share, basic and diluted	$ (0.01)	$ (0.05)	$ (0.04)	$ (0.11)
Weighted average common shares outstanding–basic and diluted	201,085,497	57,844,835	138,284,625	56,034,097
Product [Member]
Total revenue	$ 97,193	$ 315,174	$ 326,253	$ 972,308
Sales Related Party [Member]
Total revenue			198,800
License [Member]
Total revenue	$ 7,816	$ 8,526	$ 23,448	$ 26,349

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Royalty expenses, related party	$ 105,000	$ 315,000	$ 180,000
Administrative Expenses Related Party	$ 218,772	$ 628,742

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Preferred Stock [Member]Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Shares to be Issued [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2019		$ 49,087	$ 5,619,733	$ 2,847,868	$ (8,237,748)		$ 278,940
Balance, shares at Dec. 31, 2019		49,087,255
Fair value of shares for services		$ 1,541	24,009	946,488			972,038
Fair value of shares for services, shares		750,000
Shares issued for cash		$ 1,111	103,611				104,722
Shares issued for cash, shares		388,889
Fair value of shares issued to employees and officer			104,474				104,474
Fair value of shares issued to employees and officer, shares		451,198
Fair value of preferred shares issued to officer	$ 2,500		462,500				465,000
Fair value of perferred shares issued to officer, shares	2,500,000
Beneficial conversion feature of issued convertible notes			1,568,677				1,568,677
Shares to be issued for cash				19,897			19,897
Shares to be issued for cash, shares
Fair Value of shares issued for loan fees		$ 1,085	95,047	10,890			107,022
Fair Value of shares issued for loan fees, shares		1,127,522
Issuance of shares		$ 5,000	499,995	(504,995)
Issuance of shares, shares		5,018,519
Fair value of vested options			248,648				248,648
Fair value of vested restricted stock
Shares to be issued for conversion of convertible notes		$ 3,956	207,876				211,832
Shares to be issued for conversion of convertible notes, shares		3,955,747
Net loss					(5,931,371)		(5,931,371)
Balance at Sep. 30, 2020	$ 2,500	$ 61,780	8,934,570	3,320,148	(14,169,119)		(1,850,121)
Balance, shares at Sep. 30, 2020	2,500,000	60,779,130
Balance at Jun. 30, 2020	$ 2,500	$ 56,901	7,474,028	3,115,763	(11,462,649)		(813,457)
Balance, shares at Jun. 30, 2020	2,500,000	56,900,978
Fair value of shares for services		$ 543	(161,572)	184,488			23,459
Fair value of shares for services, shares		(500,117)
Fair value of shares issued to employees and officer			52,220				52,220
Fair value of shares issued to employees and officer, shares
Beneficial conversion feature of issued convertible notes			1,277,677				1,277,677
Shares to be issued for cash				19,897			19,897
Shares to be issued for cash, shares
Fair Value of shares issued for loan fees		$ 380	16,609				16,989
Fair Value of shares issued for loan fees, shares		422,522
Fair value of vested options			67,732				67,732
Shares to be issued for conversion of convertible notes		$ 3,956	207,876				211,832
Shares to be issued for conversion of convertible notes, shares		3,955,747
Net loss					(2,706,470)		(2,706,470)
Balance at Sep. 30, 2020	$ 2,500	$ 61,780	8,934,570	3,320,148	(14,169,119)		(1,850,121)
Balance, shares at Sep. 30, 2020	2,500,000	60,779,130
Balance at Dec. 31, 2020	$ 2,500	$ 46,757	10,102,805	3,641,868	(16,402,176)		(2,608,246)
Balance, shares at Dec. 31, 2020	2,500,000	46,756,970
Fair value of shares for services		$ 14,964	1,301,920				1,316,884
Fair value of shares for services, shares		14,964,425
Adjustment for adoption of ASU 2020-6			(823,655)		320,602		(503,053)
Shares issued for cash		$ 56,750	1,928,250				1,985,000
Shares issued for cash, shares		56,750,000
Fair value of vested options			34,905				34,905
Fair value of vested restricted stock				382,544			382,544
Shares to be issued for conversion of convertible notes		$ 89,137	1,454,433				1,543,570
Shares to be issued for conversion of convertible notes, shares		89,133,190
Net loss					(6,218,659)	(731,648)	(6,950,307)
Balance at Sep. 30, 2021	$ 2,500	$ 207,608	13,998,658	4,024,412	(22,300,233)	(731,648)	(4,798,703)
Balance, shares at Sep. 30, 2021	2,500,000	207,604,585
Balance at Jun. 30, 2021	$ 2,500	$ 191,805	13,867,853	3,939,659	(21,258,289)	(549,022)	(3,805,494)
Balance, shares at Jun. 30, 2021	2,500,000	191,801,218
Fair value of shares for services		$ 38	2,088				2,126
Fair value of shares for services, shares		38,449
Fair value of vested restricted stock				84,753			84,753
Cancellation of previously recognized fair value of vested options			(92,000)				(92,000)
Cancellation of previously recognized fair value of vested options, shares
Shares to be issued for conversion of convertible notes		$ 15,765	220,717				236,482
Shares to be issued for conversion of convertible notes, shares		15,764,918
Net loss					(1,041,944)	(182,626)	(1,224,570)
Balance at Sep. 30, 2021	$ 2,500	$ 207,608	$ 13,998,658	$ 4,024,412	$ (22,300,233)	$ (731,648)	$ (4,798,703)
Balance, shares at Sep. 30, 2021	2,500,000	207,604,585

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2021	Sep. 30, 2020
Preferred Stock, Par or Stated Value Per Share	$ 0.001
Common Stock [Member]
Common Stock, Par or Stated Value Per Share	0.001	$ 0.001
Series A Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
CASH FLOW FROM OPERATING ACTIVITIES:
Net loss	$ (6,950,307)	$ (5,931,371)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	52,752	161,707
Fair value of shares issued for services	1,316,884	1,068,045
Fair value of vested options	34,905	249,619
Fair value of vested restricted shares	382,544
Fair value of mezzanine equity Series B and Series C preferred shares issued for services	1,691,331
Fair value of preferred shares issued to officer		465,000
Fair value of shares issued to employees and officer		106,214
Amortization of convertible note discount	125,322	395,789
Amortization of note payable discount	21,150
Amortization of right-of-use asset	61,744	106,863
Impairment of operating lease right-of-use asset		255,093
Deferred finance charges	167,738
Fee notes issued		60,000
Accretion of premium	113,294	225,686
Change in fair value of derivative		(101,226)
Loss on extinguishment of debt		795,491
Net gain on settlement of accounts payable and accrued expenses		(16,770)
Changes in operating assets and liabilities:
Accounts receivable	685	22,143
Accounts receivable, related party	(129,300)
Bad debt expense	79,600
Allowance for doubtful accounts	49,700
Deferred expenses, related party	134,704
Inventories	(54,528)	(34,793)
Prepaid production costs	(300,000)	7,500
Accounts payable and accrued liabilities	(38,088)	387,295
Advances	106,000
Deferred revenue	(23,448)	(25,578)
Operating lease liabilities	(59,596)
Net cash used in operating activities	(3,216,914)	(1,803,293)
CASH FLOW FROM INVESTING ACTIVITIES:
Purchase of equipment	(39,290)	(80,272)
Net cash used in investment activities	(39,290)	(80,272)
CASH FLOW FROM FINANCING ACTIVITIES:
Proceeds from shares issued for cash	1,985,000	124,371
Proceeds from convertibles notes payable	1,532,955	712,000
Proceeds from notes payable		378,285
Proceeds from shares to be issued		50,000
Proceeds from revenue sharing loan		250,000
Proceeds from PPP and EIDL loans		294,125
Principal payments of notes payable	(245,759)	(65,377)
Principal payments of convertible notes payable		(282,000)
Net cash provided by financing activities	3,272,196	1,461,404
Increase (decrease) in cash	15,992	(422,161)
Cash and cash equivalents, beginning of period	6,270	433,099
Cash and cash equivalents, end of period	22,262	10,938
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	59,749	17,930
Non-cash investing and financing activities
Adjustment for adoption of ASU 2020-06	503,053
Common shares issued for conversion of convertible notes and accrued interest	1,543,570	211,832
Fees paid through conversion of notes	69,527
Recognition of beneficial conversion feature of issued convertible notes payable		1,277,677
Derivative liabilities allocated to convertible note discount		153,000
Recognition of operating lease right-of-use asset and operating lease liabilities		$ 431,402

DESCRIPTION OF BUSINESS AND SUM

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Quanta, Inc. (the “Company”) is an applied science company focused on increasing energy levels in plant matter to increase performance within the human body. The Company’s operations are based in Burbank, California. Basis of presentation-Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods have been included. The results of operations for the three months and nine months ended September 30, 2021, are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2021. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2020 and notes thereto contained in the Annual Report on Form 10-K of the Company as filed with the SEC on April 15, 2021. The condensed consolidated balance sheet as of December 31, 2020 included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP. The consolidated financial statements include the accounts of Quanta Inc, and its 51 Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, for the nine months ended September 30, 2021, the Company incurred a net loss of $ 6,950,307 and used cash in operating activities of $ 3,216,914 , and at September 30, 2021, the Company had a stockholders’ deficit of $ 4,798,703 . These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s December 31, 2020 financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. At September 30, 2021, the Company had cash on hand in the amount of $ 22,262 Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant accounting estimates include certain assumptions related to, among others, allowance for doubtful accounts receivable, impairment analysis of long-term assets, valuation allowance on deferred income taxes, assumptions used in valuing stock instruments issued for services, assumptions made in valuing derivative liabilities, and the accrual of potential liabilities. Actual results may differ from these estimates. Revenue recognition Product Sales License revenue Cost of goods sold includes direct costs and fees related to the sale of our products. Convertible Notes with Fixed Rate Conversion Options The Company may enter into convertible notes, some of which contain, predominantly, fixed rate conversion features, whereby the outstanding principal and accrued interest may be converted by the holder, into common shares at a fixed discount to the market price of the common stock at the time of conversion. This results in a fair value of the convertible note being equal to a fixed monetary amount. The Company records the convertible note liability at its fixed monetary amount by measuring and recording a premium, as applicable, on the Note date with a charge to interest expense in accordance with ASC 480 - “Distinguishing Liabilities from Equity”. Stock-based compensation The Company periodically issues stock options, warrants, shares of common stock, and restricted stock unit awards, as share-based compensation to employees and non-employees. The Company accounts for its share-based compensation in accordance with FASB ASC 718, Compensation – Stock Compensation The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods. Prepaid production costs In February 2021, the Company’s subsidiary Medolife Rx entered into a collaboration and joint development agreement with a company (the “Agent) for Medolife to produce some of its products in the Agent’s facility. Medolife Rx agreed to pay the Agent $ 300,000 Advertising costs Advertising costs are expensed as incurred. During the nine months ended September 30, 2021 and September 30, 2020, advertising costs totaled $ 659,626 61,284 Research and Development Costs Costs incurred for research and development are expensed as incurred. During the nine months ended September 30, 2021 and September 30, 2020, research and development costs totaled $ 348,500 and $ 306,544 , respectively and includes salaries, benefits, and overhead costs of personnel conducting research and development of the Company’s products. Net Loss per Share Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Shares used in the calculation of basic net loss per common share include vested but unissued shares underlying awards of restricted common stock. Diluted loss per share reflects the potential dilution, using the treasury stock method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the loss of the Company. In computing diluted loss per share, the treasury stock method assumes that outstanding warrants and convertible notes are exercised and the proceeds are used to purchase common stock at the average market price during the period. Warrants and convertible notes may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. For the nine months ended September 30, 2021 and 2020, the dilutive impact of common stock equivalents, e.g. stock options, warrants and convertible notes payable have been excluded from calculation of weighted average shares because their impact on the loss per share is anti-dilutive. As of September 30, 2021, convertible notes of $ 2,018,564 124,116,500 It should be noted that contractually the limitations on the third-party notes (and the related warrant) limit the number of shares converted to either 4.99% or 9.99% of the then outstanding shares. SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES September 30, 2021 September 30, 2020 Stock options 775,000 2,732,261 Unvested restricted shares 1,375,000 4,500,000 Convertible notes payable 124,116,500 61,171,291 Total 126,266,500 68,403,552 Fair Value of Financial Instruments The Company follows the authoritative guidance issued by the Financial Accounting Standards Board (“FASB”) for fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s assumptions. The Company is required to use of observable market data if such data is available without undue cost and effort. The Company believes the carrying amount reported in the balance sheet for cash, accounts receivable, accounts payable and accrued liabilities, and notes payable, approximate their fair values because of the short-term nature of these financial instruments. As of September 30, 2021 and December 31, 2020, the Company did not have any Level 2 liabilities comprised of the fair value of embedded derivative liabilities. Concentrations of risks For the nine months ended September 30, 2021, one customer accounted for 36 15 17 As of September 30, 2021, two vendors accounted for 82 11 17 14 14 10 The Company maintains the majority of its cash balances with one financial institution, in the form of demand deposits that are insured by the Federal Deposit Insurance Corporation, or FDIC. At times, deposits held may exceed the amount of insurance provided by the FDIC. The Company has not experienced any losses in its cash and believes it is not exposed to any significant credit risk. Segments The Company operates in one Segment Reporting Recent Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) 823,655 320,602 503,053 In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 2 – INVENTORIES Inventories are valued at the lower of cost (first-in, first-out) or net realizable value, and net of reserves, consisted of the following: SCHEDULE OF INVENTORIES September 30, 2021 December 31, 2020 Raw materials and packaging $ 32,333 $ 3,144 Finished goods 41,415 16,076 Inventories $ 73,748 $ 19,220 The Company has recorded a reserve for slow moving and potentially obsolete inventory. The reserve at September 30, 2021 and December 31, 2020 was $ 73,125 and $ 9,125 , respectively.

EQUIPMENT

EQUIPMENT	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
EQUIPMENT	NOTE 3 - EQUIPMENT Equipment, stated at cost, less accumulated depreciation consisted of the following: SCHEDULE OF EQUIPMENT September 30, 2021 December 31, 2020 Equipment $ 704,772 $ 704,772 Equipment under construction 75,259 35,969 Equipment, gross 780,031 740,741 Less accumulated depreciation (592,970 ) (540,218 ) Equipment, net $ 187,061 $ 200,523 Depreciation expense for the nine months ended September 30, 2021 and 2020 was $ 52,752 and $ 161,707 , respectively. As of September 30, 2021, the equipment under construction is approximately 70 % complete, and is expected to be completed and placed into service during the year ended December 31, 2021. Equipment under construction is depreciated only after the asset is placed in service

OPERATING LEASE

OPERATING LEASE	9 Months Ended
	Sep. 30, 2021
Operating Lease
OPERATING LEASE	NOTE 4 - OPERATING LEASE At September 30, 2021, the Company has one operating lease for its headquarters office space in Burbank. The lease commenced on January 1, 2020, and has a term for 5 years, with annual fixed rental payments ranging from $ 90,000 to $ 101,296 . At September 30, 2021, the balance of the lease’s right of use asset and corresponding lease liability were $ 300,483 and $ 336,185 , respectively. At September 30, 2021, the Company is also obligated under a lease that was abandoned in December 2020. The total due to the lessor for the abandoned lease space is $ 235,759 and is recorded as lease settlement obligation at September 30, 2021. The components of lease expense and supplemental cash flow information related to leases for the period are as follows: SCHEDULE OF LEASE EXPENSE AND SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES Nine months ended September 30, 2021 Lease Cost Operating lease cost (included in selling, general, and administrative expense in the Company’s statement of operations) $ 95,586 Other Information Cash paid for amounts included in the measurement of lease liabilities for 2021 $ 93,165 Weighted average remaining lease term – operating leases (in years) 2.50 Average discount rate – operating leases 4 % SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES At September 30, 2021 Operating leases Long-term right-of-use assets $ 300,483 Short-term operating lease liabilities $ 105,443 Long-term operating lease liabilities 230,742 Total operating lease liabilities $ 336,185 Maturities of the Company’s lease liabilities are as follows: SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES Year Ending Operating Leases 2021(remainder of year) 26,286 2022 95,481 2023 98,345 2024 139,767 Total lease payments 359,879 Less: Imputed interest (23,694 ) Present value of lease liabilities 336,185 Less current portion (105,443 ) Operating lease liabilities, long-term $ 230,742 Lease expense was $ 95,586 and $ 171,333 during the nine months ended September 30, 2021 and 2020, respectively.

NOTES PAYABLE

NOTES PAYABLE	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 5 – NOTES PAYABLE SCHEDULE OF NOTES PAYABLE September 30, 2021 December 31, 2020 (a) Notes payable secured by equipment $ 212,875 $ 438,634 (b) Note payable, secured by assets-in default 13,350 33,350 (c) Note payable, Payroll Protection Program 134,125 134,125 (d) Note payable, Economic Injury Disaster Loan 160,000 160,000 (e) Revenue sharing agreement 242,800 242,800 Total notes payable outstanding 763,150 1,008,909 Debt discount (53,667 ) (74,817 ) Notes payable, net of discount 709,483 934,092 Less: Current portion 415,358 482,724 Long term portion $ 294,125 $ 451,368 (a) In April 2020 and May 2020, the Company entered into two financing agreements aggregating $ 505,646 10.9 21,000 April 2022 and May 2022 438,634 225,759 212,875 53,667 74,817 (b) Note payable, interest at 8.3 due January 13, 2019 20,000 13,350 (c) On May 7, 2020, the Company was granted a loan (the “PPP loan”) from Bank of America in the aggregate amount of $ 134,125 The PPP loan agreement is dated May 4, 2020, matures on May 4, 2022 1 April 20, 2025 Debt (d) On September 5, 2020, the Company received a $ 160,000 3.75 (e) Between July 7, 2020, and July 29, 2020, the Company issued notes payable to third-party investors totaling $ 250,000 7,200 Under the terms of the notes, the Company is to pay 50% of the net revenues beginning on August 21, 2020, for a product to be designed and produced by the Company. The product has not been produced and therefore no payments have been made 146,000

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE	NOTE 6 – CONVERTIBLE NOTES PAYABLE Convertible notes payable consisted of the following: SCHEDULE OF CONVERTIBLE NOTES PAYABLE September 30, 2021 December 31, 2020 Unsecured (a) Convertible notes with fixed discount percentage conversion prices $ 264,500 $ 180,200 Put premiums on stock settled debt 113,294 127,866 (b) Convertible notes with fixed conversion prices 1,845,000 936,944 Default penalty principal added - 369,086 Total convertible notes principal outstanding 2,222,794 1,614,096 Debt discount (204,230 ) (539,282 ) Convertible notes, net of discount and premium $ 2,018,564 $ 1,074,814 Less; Current portion 2,018,564 1,074,814 Long-term portion $ - $ - (a) At December 31, 2020, the balance due on convertible notes with fixed discount percentage conversion prices was $ 180,200 117,866 264,500 25 35 113,294 180,200 18,266 198,466 7,492,676 127,866 264,500 (b) As of December 31, 2020, the balance due on convertible notes with fixed conversion prices was $ 1,306,030 369,086 1,565,000 1,030,345 43,349 1,073,694 81,640,514 1,845,000 0.015 0.04 4 10 At December 31, 2020, the net unamortized balance of debt discounts was $ 539,282 823,655 320,602 503,053 52,360 16,096 36,229 823,655 320,602 503,053 The debt discounts related to fees and OID are amortized over the life of the related notes or are amortized in full upon the conversion of the corresponding note to common stock. During the nine months ended September 30, 2021, debt discounts of $ 295,600 146,472 204,230 On May 4, 2021 (“Effective Date”), the Company entered into a securities purchase agreement (the “SPA”) with Clifton Royale Apartments, LLC (the “Investor”) pursuant to which the Company issued a 4 80,000 80,000 The maturity date of the Note was November 4, 2021 4 The Investor is entitled to, at its option, convert all or any amount of the principal amount and any accrued but unpaid interest of the Investor Note into Common Stock, at any time, at a fixed conversion price for each share of Common Stock equal to $0.01 (as defined in the Note) of the Common Stock as reported on the OTC Marketplace exchange upon which the Company’s shares are traded during the twenty (20) consecutive Trading Day period immediately preceding (i) the applicable Effective Date; or (ii) the conversion date 15,000,000

MEZZANINE EQUITY

MEZZANINE EQUITY	9 Months Ended
	Sep. 30, 2021
Mezzanine Equity
MEZZANINE EQUITY	NOTE 7 – MEZZANINE EQUITY The Company has determined that its shares of the Series B and Series C convertible preferred stock are conditionally redeemable upon the occurrence of certain events that are not solely within the control of the issuer, and upon such event, the shares would become redeemable at the option of the holders; accordingly the Series B and Series C convertible preferred stock are classified as “mezzanine equity” (temporary equity), between liabilities and stockholders’ deficit. The purpose of this classification is to convey that such a security may not be permanently part of equity and could result in a demand for cash, securities or other assets of the entity in the future. The shares as valued have been classified as mezzanine equity and presented as such on the consolidated balance sheet at September 30, 2021 as single line items due to the immaterial par value. The mezzanine equity value is not included in shareholders’ deficit. Series B Convertible Preferred Stock The terms of the Certificate of Designation of the Series B Convertible Preferred Stock, which was filed with the State of Nevada on January 12, 2021, state that the shares of Series B Convertible Preferred Stock are convertible into fifty-four percent (54%) of the issued and outstanding shares of the Company’s common stock on a fully converted basis 6,750 On December 21, 2020, the Company entered into a Securities Exchange Agreement with Medolife Rx, Inc., a Wyoming corporation, (“Medolife Rx”) pursuant to which, the Company agreed to acquire 51% 9,000 1,522,198 Series C Convertible Preferred Stock The terms of the Certificate of Designation of the Series C Convertible Preferred Stock, which was filed with the State of Nevada on January 12, 2021, state that such Series C Convertible shares have a par value of $ 0.00001 100 6,750 On January 14, 2021, the Board of Directors of the Company approved the issuance of all 1,000 500 500 169,133

STOCKHOLDERS_ DEFICIT

STOCKHOLDERS’ DEFICIT	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 8 – STOCKHOLDERS’ DEFICIT Common Stock Common stock issued for cash During the nine months ended September 30, 2021, the Company issued 44,750,000 0.04 12,000,000 0.015 0.02 1,985,000 During the nine months ended September 30, 2020, the Company issued 407,408 0.26 124,371 Common stock issued for services During the nine months ended September 30, 2021, the Company issued 13,964,425 1,246,934 1,000,000 69,950 During the nine months ended September 30, 2020, the Company issued 451,198 104,474 During the nine months ended September 30, 2020, the Company issued 750,000 209,495 During the nine months ended September 30, 2020, the Company issued 1,127,522 107,022 Preferred Stock On April 14, 2020, the Company issued 2,500,000 465,000 Restricted common stock In 2019, the Company agreed to issue 8,000,000 shares of the Company’s common stock with vesting terms to Arthur Mikaelian. 1,000,000 shares vested immediately, and the balance of 7,000,000 shares vest 625,000 shares per quarter over 2.8 . The Company accounts for the share awards using a graded vesting attribution method over the requisite service period, as if each tranche were a separate award. During the nine months ended September 30, 2021 and 2020, total share-based expense recognized related to vested restricted shares totaled $ 382,544 and $ 762,543 , respectively. At September 30, 2021, there was $ 48,867 of unvested compensation related to these awards that will be amortized over a remaining vesting period of approximately six months thru March 2022. The following table summarizes restricted common stock activity for the nine months ended September 30, 2021: SUMMARY OF RESTRICTED COMMON STOCK ACTIVITY Number of shares Fair value of shares Non-vested shares, December 31, 2020 3,250,000 431,411 Granted - - Vested (1,875,000 ) (382,544 ) Forfeited - - Non-vested shares, September 30, 2021 1,375,000 $ 48,867 As of September 30, 2021, no shares have been issued and 4,875,000 vested shares are included in shares to be issued on the accompanying statement of stockholders’ deficit. Common stock issued in conversion of convertible notes payable During the nine months ended September 30, 2021, the Company issued 89,133,190 1,543,570 Stock Options During the nine months ended September 30, 2021 and 2020, the Company recognized $ 34,905 248,648 , respectively, of compensation expense relating to vested stock options. During the nine months ended September 30, 2021, the Company did not issue any options. In April 2020, the Company issued options exercisable into 300,000 shares of common stock which vested immediately. The options have an exercise price of $ 0.14 per share, and expire in 10 . The total fair value of these options at grant date was approximately $ 30,000 , which was determined using the Black-Scholes-Merton option pricing model with the following average assumption: stock price $0.14 per share, expected term ranging from five years , volatility 236% , dividend rate of 0% and risk-fee interest rate of 0.17% . The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement corresponding with the expected term of the share option award; the expected term represents the weighted-average period of time that share option awards granted are expected to be outstanding giving consideration to vesting schedules and historical participant exercise behavior; the expected volatility is based upon historical volatility of the Company’s common stock; and the expected dividend yield is based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future. As of September 30, 2021, the amount of unvested compensation related to stock options was approximately $ 22,000 which will be recorded as an expense in future periods as the options vest. A summary of stock option activity during the nine months ended September 30, 2021: SCHEDULE OF STOCK OPTION ACTIVITY Number of options Weighted Average Contractual Options Outstanding as of December 31, 2020 4,130,000 0.10 6.0 Granted - - - Exercised (350,000 ) - - Forfeited (3,005,000 ) - - Options Outstanding as of September 30, 2021 775,000 0.10 5.5 Options Exercisable as of September 30, 2021 775,000 $ 0.10 5.5 At September 30, 2021, the options outstanding had no intrinsic value.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9 – RELATED PARTY TRANSACTIONS On January 14, 2021, the Company completed the acquisition of 51% 51% The Company has an agreement with Mr. Mikaelian in consideration of the Company’s exclusive use of patented technology developed by Mr. Mikaelian. Pursuant to the agreement, as amended, the Company shall pay a royalty of 25% 35,000 315,000 180,000 During the nine months ended September 30, 2021, the Company recorded revenue of $ 198,800 from a company controlled by a family member of the Company’s CEO. At September 30, 2021, the related accounts receivable balance of $ 198,800 During the nine months ended September 30, 2021, the Company recorded administrative expenses of $ 628,742

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 10 – COMMITMENTS AND CONTINGENCIES COVID-19 During the nine months ended September 30, 2021, the COVID-19 pandemic has impacted our operating results and the Company anticipates a continued impact for the balance of the year. In addition, the pandemic may cause reduced demand for our products if, for example, the pandemic results in a recessionary economic environment which negatively effects the consumers who purchase our products. The Company monitors guidance from federal, state, and local public health authorities, and has implemented health and safety precautions and protocols in response to these guidelines. The extent of the impact of the COVID-19 pandemic has had and will continue to have on the Company’s business is highly uncertain and difficult to predict and quantify at this time. Contingencies include obligations for lease agreements, including an abandoned lease space, along with the Company current lease for its headquarters office (see Note 4).

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 – SUBSEQUENT EVENTS Common Stock Issued Subsequent to September 30, 2021, the Company issued a total of 7,128,571 shares of common stock to convertible note holders in exchange for the conversion of convertible notes payable and accrued interest. On November 12, 2021 (“Effective Date”), the Company entered into a securities purchase agreement (the “SPA”) with Trillium Partners LP (the “Investor”) pursuant to which the Company issued a 12 82,500 75,000 The maturity date of the Note was November 12, 2022 12 The Investor is entitled to, at its option, convert all or any amount of the principal amount and any accrued but unpaid interest of the Investor Note into Common Stock, at any time, at a fixed conversion price for each share of Common Stock equal to $0.01 (as defined in the Note) of the Common Stock as reported on the OTC Marketplace exchange upon which the Company’s shares are traded during the twenty (20) consecutive Trading Day period immediately preceding (i) the applicable Effective Date; or (ii) the conversion date. 8,250,000 The Company initially reserved 30,000,000

DESCRIPTION OF BUSINESS AND S_2

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of presentation-Unaudited Interim Financial Information	Basis of presentation-Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods have been included. The results of operations for the three months and nine months ended September 30, 2021, are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2021. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2020 and notes thereto contained in the Annual Report on Form 10-K of the Company as filed with the SEC on April 15, 2021. The condensed consolidated balance sheet as of December 31, 2020 included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP. The consolidated financial statements include the accounts of Quanta Inc, and its 51
Going Concern	Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, for the nine months ended September 30, 2021, the Company incurred a net loss of $ 6,950,307 and used cash in operating activities of $ 3,216,914 , and at September 30, 2021, the Company had a stockholders’ deficit of $ 4,798,703 . These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s December 31, 2020 financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. At September 30, 2021, the Company had cash on hand in the amount of $ 22,262
Use of estimates	Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant accounting estimates include certain assumptions related to, among others, allowance for doubtful accounts receivable, impairment analysis of long-term assets, valuation allowance on deferred income taxes, assumptions used in valuing stock instruments issued for services, assumptions made in valuing derivative liabilities, and the accrual of potential liabilities. Actual results may differ from these estimates.
Revenue recognition	Revenue recognition Product Sales License revenue Cost of goods sold includes direct costs and fees related to the sale of our products.
Convertible Notes with Fixed Rate Conversion Options	Convertible Notes with Fixed Rate Conversion Options The Company may enter into convertible notes, some of which contain, predominantly, fixed rate conversion features, whereby the outstanding principal and accrued interest may be converted by the holder, into common shares at a fixed discount to the market price of the common stock at the time of conversion. This results in a fair value of the convertible note being equal to a fixed monetary amount. The Company records the convertible note liability at its fixed monetary amount by measuring and recording a premium, as applicable, on the Note date with a charge to interest expense in accordance with ASC 480 - “Distinguishing Liabilities from Equity”.
Stock-based compensation	Stock-based compensation The Company periodically issues stock options, warrants, shares of common stock, and restricted stock unit awards, as share-based compensation to employees and non-employees. The Company accounts for its share-based compensation in accordance with FASB ASC 718, Compensation – Stock Compensation The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods.
Prepaid production costs	Prepaid production costs In February 2021, the Company’s subsidiary Medolife Rx entered into a collaboration and joint development agreement with a company (the “Agent) for Medolife to produce some of its products in the Agent’s facility. Medolife Rx agreed to pay the Agent $ 300,000
Advertising costs	Advertising costs Advertising costs are expensed as incurred. During the nine months ended September 30, 2021 and September 30, 2020, advertising costs totaled $ 659,626 61,284
Research and Development Costs	Research and Development Costs Costs incurred for research and development are expensed as incurred. During the nine months ended September 30, 2021 and September 30, 2020, research and development costs totaled $ 348,500 and $ 306,544 , respectively and includes salaries, benefits, and overhead costs of personnel conducting research and development of the Company’s products.
Net Loss per Share	Net Loss per Share Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Shares used in the calculation of basic net loss per common share include vested but unissued shares underlying awards of restricted common stock. Diluted loss per share reflects the potential dilution, using the treasury stock method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the loss of the Company. In computing diluted loss per share, the treasury stock method assumes that outstanding warrants and convertible notes are exercised and the proceeds are used to purchase common stock at the average market price during the period. Warrants and convertible notes may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. For the nine months ended September 30, 2021 and 2020, the dilutive impact of common stock equivalents, e.g. stock options, warrants and convertible notes payable have been excluded from calculation of weighted average shares because their impact on the loss per share is anti-dilutive. As of September 30, 2021, convertible notes of $ 2,018,564 124,116,500 It should be noted that contractually the limitations on the third-party notes (and the related warrant) limit the number of shares converted to either 4.99% or 9.99% of the then outstanding shares. SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES September 30, 2021 September 30, 2020 Stock options 775,000 2,732,261 Unvested restricted shares 1,375,000 4,500,000 Convertible notes payable 124,116,500 61,171,291 Total 126,266,500 68,403,552
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company follows the authoritative guidance issued by the Financial Accounting Standards Board (“FASB”) for fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s assumptions. The Company is required to use of observable market data if such data is available without undue cost and effort. The Company believes the carrying amount reported in the balance sheet for cash, accounts receivable, accounts payable and accrued liabilities, and notes payable, approximate their fair values because of the short-term nature of these financial instruments. As of September 30, 2021 and December 31, 2020, the Company did not have any Level 2 liabilities comprised of the fair value of embedded derivative liabilities.
Concentrations of risks	Concentrations of risks For the nine months ended September 30, 2021, one customer accounted for 36 15 17 As of September 30, 2021, two vendors accounted for 82 11 17 14 14 10 The Company maintains the majority of its cash balances with one financial institution, in the form of demand deposits that are insured by the Federal Deposit Insurance Corporation, or FDIC. At times, deposits held may exceed the amount of insurance provided by the FDIC. The Company has not experienced any losses in its cash and believes it is not exposed to any significant credit risk.
Segments	Segments The Company operates in one Segment Reporting
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) 823,655 320,602 503,053 In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

DESCRIPTION OF BUSINESS AND S_3

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES	SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES September 30, 2021 September 30, 2020 Stock options 775,000 2,732,261 Unvested restricted shares 1,375,000 4,500,000 Convertible notes payable 124,116,500 61,171,291 Total 126,266,500 68,403,552

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORIES	Inventories are valued at the lower of cost (first-in, first-out) or net realizable value, and net of reserves, consisted of the following: SCHEDULE OF INVENTORIES September 30, 2021 December 31, 2020 Raw materials and packaging $ 32,333 $ 3,144 Finished goods 41,415 16,076 Inventories $ 73,748 $ 19,220

EQUIPMENT (Tables)

EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
SCHEDULE OF EQUIPMENT	Equipment, stated at cost, less accumulated depreciation consisted of the following: SCHEDULE OF EQUIPMENT September 30, 2021 December 31, 2020 Equipment $ 704,772 $ 704,772 Equipment under construction 75,259 35,969 Equipment, gross 780,031 740,741 Less accumulated depreciation (592,970 ) (540,218 ) Equipment, net $ 187,061 $ 200,523

OPERATING LEASE (Tables)

OPERATING LEASE (Tables)	9 Months Ended
	Sep. 30, 2021
Operating Lease
SCHEDULE OF LEASE EXPENSE AND SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES	The components of lease expense and supplemental cash flow information related to leases for the period are as follows: SCHEDULE OF LEASE EXPENSE AND SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES Nine months ended September 30, 2021 Lease Cost Operating lease cost (included in selling, general, and administrative expense in the Company’s statement of operations) $ 95,586 Other Information Cash paid for amounts included in the measurement of lease liabilities for 2021 $ 93,165 Weighted average remaining lease term – operating leases (in years) 2.50 Average discount rate – operating leases 4 %
SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES	SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES At September 30, 2021 Operating leases Long-term right-of-use assets $ 300,483 Short-term operating lease liabilities $ 105,443 Long-term operating lease liabilities 230,742 Total operating lease liabilities $ 336,185
SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES	Maturities of the Company’s lease liabilities are as follows: SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES Year Ending Operating Leases 2021(remainder of year) 26,286 2022 95,481 2023 98,345 2024 139,767 Total lease payments 359,879 Less: Imputed interest (23,694 ) Present value of lease liabilities 336,185 Less current portion (105,443 ) Operating lease liabilities, long-term $ 230,742

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
SCHEDULE OF NOTES PAYABLE	SCHEDULE OF NOTES PAYABLE September 30, 2021 December 31, 2020 (a) Notes payable secured by equipment $ 212,875 $ 438,634 (b) Note payable, secured by assets-in default 13,350 33,350 (c) Note payable, Payroll Protection Program 134,125 134,125 (d) Note payable, Economic Injury Disaster Loan 160,000 160,000 (e) Revenue sharing agreement 242,800 242,800 Total notes payable outstanding 763,150 1,008,909 Debt discount (53,667 ) (74,817 ) Notes payable, net of discount 709,483 934,092 Less: Current portion 415,358 482,724 Long term portion $ 294,125 $ 451,368 (a) In April 2020 and May 2020, the Company entered into two financing agreements aggregating $ 505,646 10.9 21,000 April 2022 and May 2022 438,634 225,759 212,875 53,667 74,817 (b) Note payable, interest at 8.3 due January 13, 2019 20,000 13,350 (c) On May 7, 2020, the Company was granted a loan (the “PPP loan”) from Bank of America in the aggregate amount of $ 134,125 The PPP loan agreement is dated May 4, 2020, matures on May 4, 2022 1 April 20, 2025 Debt (d) On September 5, 2020, the Company received a $ 160,000 3.75 (e) Between July 7, 2020, and July 29, 2020, the Company issued notes payable to third-party investors totaling $ 250,000 7,200 Under the terms of the notes, the Company is to pay 50% of the net revenues beginning on August 21, 2020, for a product to be designed and produced by the Company. The product has not been produced and therefore no payments have been made 146,000

CONVERTIBLE NOTES PAYABLE (Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
SCHEDULE OF CONVERTIBLE NOTES PAYABLE	Convertible notes payable consisted of the following: SCHEDULE OF CONVERTIBLE NOTES PAYABLE September 30, 2021 December 31, 2020 Unsecured (a) Convertible notes with fixed discount percentage conversion prices $ 264,500 $ 180,200 Put premiums on stock settled debt 113,294 127,866 (b) Convertible notes with fixed conversion prices 1,845,000 936,944 Default penalty principal added - 369,086 Total convertible notes principal outstanding 2,222,794 1,614,096 Debt discount (204,230 ) (539,282 ) Convertible notes, net of discount and premium $ 2,018,564 $ 1,074,814 Less; Current portion 2,018,564 1,074,814 Long-term portion $ - $ - (a) At December 31, 2020, the balance due on convertible notes with fixed discount percentage conversion prices was $ 180,200 117,866 264,500 25 35 113,294 180,200 18,266 198,466 7,492,676 127,866 264,500 (b) As of December 31, 2020, the balance due on convertible notes with fixed conversion prices was $ 1,306,030 369,086 1,565,000 1,030,345 43,349 1,073,694 81,640,514 1,845,000 0.015 0.04 4 10 At December 31, 2020, the net unamortized balance of debt discounts was $ 539,282 823,655 320,602 503,053 52,360 16,096 36,229 823,655 320,602 503,053 The debt discounts related to fees and OID are amortized over the life of the related notes or are amortized in full upon the conversion of the corresponding note to common stock. During the nine months ended September 30, 2021, debt discounts of $ 295,600 146,472 204,230 On May 4, 2021 (“Effective Date”), the Company entered into a securities purchase agreement (the “SPA”) with Clifton Royale Apartments, LLC (the “Investor”) pursuant to which the Company issued a 4 80,000 80,000 The maturity date of the Note was November 4, 2021 4 The Investor is entitled to, at its option, convert all or any amount of the principal amount and any accrued but unpaid interest of the Investor Note into Common Stock, at any time, at a fixed conversion price for each share of Common Stock equal to $0.01 (as defined in the Note) of the Common Stock as reported on the OTC Marketplace exchange upon which the Company’s shares are traded during the twenty (20) consecutive Trading Day period immediately preceding (i) the applicable Effective Date; or (ii) the conversion date 15,000,000

STOCKHOLDERS_ DEFICIT (Tables)

STOCKHOLDERS’ DEFICIT (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
SUMMARY OF RESTRICTED COMMON STOCK ACTIVITY	The following table summarizes restricted common stock activity for the nine months ended September 30, 2021: SUMMARY OF RESTRICTED COMMON STOCK ACTIVITY Number of shares Fair value of shares Non-vested shares, December 31, 2020 3,250,000 431,411 Granted - - Vested (1,875,000 ) (382,544 ) Forfeited - - Non-vested shares, September 30, 2021 1,375,000 $ 48,867
SCHEDULE OF STOCK OPTION ACTIVITY	A summary of stock option activity during the nine months ended September 30, 2021: SCHEDULE OF STOCK OPTION ACTIVITY Number of options Weighted Average Contractual Options Outstanding as of December 31, 2020 4,130,000 0.10 6.0 Granted - - - Exercised (350,000 ) - - Forfeited (3,005,000 ) - - Options Outstanding as of September 30, 2021 775,000 0.10 5.5 Options Exercisable as of September 30, 2021 775,000 $ 0.10 5.5

SCHEDULE OF POTENTIALLY DILUTIV

SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	126,266,500	68,403,552
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	775,000	2,732,261
Unvested Restricted Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,375,000	4,500,000
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	124,116,500	61,171,291

DESCRIPTION OF BUSINESS AND S_4

DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	Jan. 02, 2021USD ($)	Jan. 02, 2021USD ($)	Feb. 28, 2021USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)Segmentshares	Sep. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jan. 14, 2021	Dec. 31, 2020USD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2019USD ($)
Product Information [Line Items]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest				$ 1,224,570	$ 2,706,470	$ 6,950,307	$ 5,931,371
Net Cash Provided by (Used in) Operating Activities						3,216,914	1,803,293
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest				4,798,703	1,850,121	4,798,703	1,850,121	$ 3,805,494		$ 2,608,246	$ 813,457	$ (278,940)
Cash on hand				22,262		22,262				$ 6,270
Advertising costs						659,626	61,284
Research and Development Expense				105,000	$ 62,006	348,500	$ 306,544
Convertible Notes Payable				$ 2,018,564		$ 2,018,564
Debt Conversion, Description						It should be noted that contractually the limitations on the third-party notes (and the related warrant) limit the number of shares converted to either 4.99% or 9.99% of the then outstanding shares.
Number of operating segments | Segment						1
Accounting Standards Update 2020-06 [Member]
Product Information [Line Items]
Decrease in addition paid in capital	$ 823,655
Decrease to accumulated deficit	$ 320,602	$ 320,602
Increase in convertible notes payable		$ 503,053
Customer One [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage						36.00%	15.00%
Customer One [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage							17.00%
Common Stock One [Member]
Product Information [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares						124,116,500
Salaries, Benefits and Overhead Costs [Member]
Product Information [Line Items]
Research and Development Expense						$ 348,500	$ 306,544
Two Vendors [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage						82.00%
Vendors One [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage							11.00%
Vendors Two [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage							17.00%
Vendors Three [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage							14.00%
Vendor Four [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage							14.00%
Vendor [Member] | Accounts Payable [Member] | Product Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage							10.00%
Medolife Rx, Inc [Member] | Agent [Member]
Product Information [Line Items]
Prepaid production costs			$ 300,000
Securities Exchange Agreement [Member] | Medolife Rx, Inc. [Member]
Product Information [Line Items]
Acquisition percentage				51.00%		51.00%			51.00%

SCHEDULE OF INVENTORIES (Detail

SCHEDULE OF INVENTORIES (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials and packaging	$ 32,333	$ 3,144
Finished goods	41,415	16,076
Inventories	$ 73,748	$ 19,220

INVENTORIES (Details Narrative)

INVENTORIES (Details Narrative) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Inventory, Raw Materials and Supplies, Net of Reserves	$ 73,125	$ 9,125

SCHEDULE OF EQUIPMENT (Details)

SCHEDULE OF EQUIPMENT (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Equipment, gross	$ 780,031	$ 740,741
Less accumulated depreciation	(592,970)	(540,218)
Equipment, net	187,061	200,523
Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross	704,772	704,772
Equipment Under Construction [Member]
Property, Plant and Equipment [Line Items]
Equipment, gross	$ 75,259	$ 35,969

EQUIPMENT (Details Narrative)

EQUIPMENT (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Depreciation	$ 52,752	$ 161,707
Percentage for equipment under construction	70.00%

SCHEDULE OF LEASE EXPENSE AND S

SCHEDULE OF LEASE EXPENSE AND SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES (Details)	9 Months Ended
	Sep. 30, 2021USD ($)
Operating Lease
Operating lease cost (included in selling, general, and administrative expense in the Company’s statement of operations)	$ 95,586
Cash paid for amounts included in the measurement of lease liabilities for 2021	$ 93,165
Weighted average remaining lease term - operating leases (in years)	2 years 6 months
Average discount rate - operating leases	4.00%

SCHEDULE OF SUPPLEMENTAL BALANC

SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Operating Lease
Long-term right-of-use assets	$ 300,483	$ 362,227
Short-term operating lease liabilities	105,443	100,901
Long-term operating lease liabilities	230,742	$ 294,880
Total operating lease liabilities	$ 336,185

SCHEDULE OF MATURITIES OF OPERA

SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Operating Lease
2021(remainder of year)	$ 26,286
2022	95,481
2023	98,345
2024	139,767
Total lease payments	359,879
Less: Imputed interest	(23,694)
Present value of lease liabilities	336,185
Less current portion	(105,443)	$ (100,901)
Operating lease liabilities, long-term	$ 230,742	$ 294,880

OPERATING LEASE (Details Narrat

OPERATING LEASE (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Lessee, Operating Lease, Renewal Term	5 years
[custom:OperatingLeaseRightOfUseAssets-0]	$ 300,483
Operating lease liabilities	336,185
Settlement Liabilities, Current	235,759		$ 235,759
Operating Lease, Expense	95,586	$ 171,333
Minimum [Member]
Payments for Rent	90,000
Maximum [Member]
Payments for Rent	$ 101,296

SCHEDULE OF NOTES PAYABLE (Deta

SCHEDULE OF NOTES PAYABLE (Details) - USD ($)		Sep. 30, 2021	Dec. 31, 2020	May 31, 2020	Apr. 30, 2020
Debt Disclosure [Abstract]
(a) Notes payable secured by equipment	[1]	$ 212,875	$ 438,634
(b) Note payable, secured by assets-in default	[2]	13,350	33,350
(c) Note payable, Payroll Protection Program	[3]	134,125	134,125
(d) Note payable, Economic Injury Disaster Loan	[4]	160,000	160,000
(e) Revenue sharing agreement	[5]	242,800	242,800
Total notes payable outstanding		763,150	1,008,909	$ 505,646	$ 505,646
Debt discount		(53,667)	(74,817)
Notes payable, net of discount		709,483	934,092
Less: Current portion		415,358	482,724
Long term portion		$ 294,125	$ 451,368
[1]	In April 2020 and May 2020, the Company entered into two financing agreements aggregating $ 505,646 10.9 21,000 April 2022 and May 2022 438,634 225,759 212,875 53,667 74,817
[2]	Note payable, interest at 8.3 due January 13, 2019 20,000 13,350
[3]	On May 7, 2020, the Company was granted a loan (the “PPP loan”) from Bank of America in the aggregate amount of $ 134,125 The PPP loan agreement is dated May 4, 2020, matures on May 4, 2022 1 April 20, 2025 Debt
[4]	On September 5, 2020, the Company received a $ 160,000 3.75
[5]	Between July 7, 2020, and July 29, 2020, the Company issued notes payable to third-party investors totaling $ 250,000 7,200 Under the terms of the notes, the Company is to pay 50% of the net revenues beginning on August 21, 2020, for a product to be designed and produced by the Company. The product has not been produced and therefore no payments have been made 146,000

SCHEDULE OF NOTES PAYABLE (De_2

SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical) - USD ($)	Sep. 05, 2020	May 07, 2020	Jul. 29, 2020	May 31, 2020	Apr. 30, 2020	Sep. 30, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Notes payable				$ 505,646	$ 505,646	$ 763,150	$ 1,008,909
Notes bear interest				10.90%	10.90%
Monthly interest and principal payments				$ 21,000	$ 21,000
Debt instrument maturity description				April 2022 and May 2022	April 2022 and May 2022
Debt outstanding balance						225,759	438,634
Debt outstanding balance						212,875
Unamortized discount related deferred financing charges						$ 53,667	$ 74,817
EID Loan [Member]
Short-term Debt [Line Items]
Notes bear interest	3.75%
Proceeds from loans	$ 160,000
Notes Payable [Member]
Short-term Debt [Line Items]
Notes bear interest						8.30%	8.30%
Debt instrument maturity description						due January 13, 2019
Debt outstanding balance						$ 13,350
Debt maturity date						Jan. 13, 2019
Repayment of debt						$ 20,000
Notes Payable [Member] | Third Party Investors [Member]
Short-term Debt [Line Items]
Debt outstanding balance			$ 250,000
Repayment of debt			$ 7,200
Terms of notes			Under the terms of the notes, the Company is to pay 50% of the net revenues beginning on August 21, 2020, for a product to be designed and produced by the Company. The product has not been produced and therefore no payments have been made
Received notice under demand of payment			$ 146,000
PPP Loan [Member]
Short-term Debt [Line Items]
Notes bear interest		1.00%
Debt instrument maturity description		The PPP loan agreement is dated May 4, 2020, matures on May 4, 2022
Debt maturity date		Apr. 20, 2025
Proceeds from loans		$ 134,125

SCHEDULE OF CONVERTIBLE NOTES P

SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) - USD ($)		Sep. 30, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Debt discount		$ (53,667)	$ (74,817)
Convertible notes, net of discount and premium		2,018,564
Convertible Notes Payable [Member]
Short-term Debt [Line Items]
(a) Convertible notes with fixed discount percentage conversion prices	[1]	264,500	180,200
Put premiums on stock settled debt		113,294	127,866
(b) Convertible notes with fixed conversion prices	[2]	1,845,000	936,944
Default penalty principal added			369,086
Total convertible notes principal outstanding		2,222,794	1,614,096
Debt discount		(204,230)	(539,282)
Convertible notes, net of discount and premium		2,018,564	1,074,814
Less; Current portion		2,018,564	1,074,814
Long-term portion
[1]	At December 31, 2020, the balance due on convertible notes with fixed discount percentage conversion prices was $ 180,200 117,866 264,500 25 35 113,294 180,200 18,266 198,466 7,492,676 127,866 264,500
[2]	As of December 31, 2020, the balance due on convertible notes with fixed conversion prices was $ 1,306,030 369,086 1,565,000 1,030,345 43,349 1,073,694 81,640,514 1,845,000 0.015 0.04 4 10

SCHEDULE OF CONVERTIBLE NOTES_2

SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) (Parenthetical) - USD ($)	May 04, 2021	May 31, 2020	Apr. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Jan. 02, 2021
Short-term Debt [Line Items]
Debt Conversion, Converted Instrument, Amount						$ 264,500
Debt interest rate		10.90%	10.90%
[custom:DebtInstrumentPremiumAmount]						113,294
Debt Instrument, Periodic Payment		$ 21,000	$ 21,000
Debt discount				$ 53,667		53,667		$ 74,817
Debt Issuance Costs, Gross, Current				53,667		53,667		74,817
Amortization of debt discount				77,777	$ 116,566	146,472	$ 395,789
Debt face amount				$ 225,759		$ 225,759		438,634
Debt Conversion, Description						It should be noted that contractually the limitations on the third-party notes (and the related warrant) limit the number of shares converted to either 4.99% or 9.99% of the then outstanding shares.
Securities Purchase Agreement [Member] | Clifton Royale Apartments L L C [Member]
Short-term Debt [Line Items]
Debt interest rate	4.00%
Debt face amount	$ 80,000
Proceeds from Issuance of Unsecured Debt	$ 80,000
Debt maturity date	Nov. 4, 2021
Debt Conversion, Description	The Investor is entitled to, at its option, convert all or any amount of the principal amount and any accrued but unpaid interest of the Investor Note into Common Stock, at any time, at a fixed conversion price for each share of Common Stock equal to $0.01 (as defined in the Note) of the Common Stock as reported on the OTC Marketplace exchange upon which the Company’s shares are traded during the twenty (20) consecutive Trading Day period immediately preceding (i) the applicable Effective Date; or (ii) the conversion date
Warrants to purchase common stock	15,000,000
Accounting Standards Update 2020-06 [Member]
Short-term Debt [Line Items]
Decrease in addition paid in capital									$ 823,655
Decrease to accumulated deficit									320,602
[custom:IncreaseInStockholdersDeficit-0]									$ 503,053
Minimum [Member]
Short-term Debt [Line Items]
Debt interest rate				25.00%		25.00%
Maximum [Member]
Short-term Debt [Line Items]
Debt interest rate				35.00%		35.00%
Convertible Notes [Member]
Short-term Debt [Line Items]
Unsecured convertible promissory note								180,200
Interest expenses put premium						$ 127,866		117,866
[custom:DebtInstrumentPremiumAmount]						264,500
Debt Instrument, Periodic Payment, Principal						180,200
Debt Instrument, Periodic Payment, Interest						18,266
Debt Instrument, Periodic Payment						$ 198,466
Debt Conversion, Converted Instrument, Shares Issued						7,492,676
Convertible Notes, Fixed Price [Member]
Short-term Debt [Line Items]
Unsecured convertible promissory note								1,306,030
Debt Instrument, Periodic Payment, Principal						$ 1,030,345
Debt Instrument, Periodic Payment, Interest						43,349
Debt Instrument, Periodic Payment						$ 1,073,694
Debt Conversion, Converted Instrument, Shares Issued						81,640,514
Default penalties on debt								369,086
Convertible notes with fixed conversion prices				$ 1,845,000		$ 1,845,000
Debt discount								539,282
Debt beneficial conversion features gross								823,655
Debt beneficial conversion features accumulated amortization								320,602
Debt beneficial conversion features net								503,053
Debt Issuance Costs, Gross, Current								52,360
Accumulated Amortization, Debt Issuance Costs, Current								16,096
Debt Issuance Costs, Current, Net								$ 36,229
Convertible Notes, Fixed Price [Member] | Minimum [Member]
Short-term Debt [Line Items]
Debt interest rate				4.00%		4.00%
Debt Instrument, Convertible, Conversion Price				$ 0.04		$ 0.04
Convertible Notes, Fixed Price [Member] | Maximum [Member]
Short-term Debt [Line Items]
Debt interest rate				10.00%		10.00%
Debt Instrument, Convertible, Conversion Price				$ 0.015		$ 0.015
Nine Convertible Notes Fixed Prices [Member]
Short-term Debt [Line Items]
Unsecured convertible promissory note				$ 1,565,000		$ 1,565,000
Twelve Convertible Notes Fixed Prices [Member]
Short-term Debt [Line Items]
Debt discount				295,600		295,600
Amortization of debt discount						146,472
Unamortizaed other debt discount				$ 204,230		$ 204,230

MEZZANINE EQUITY (Details Narra

MEZZANINE EQUITY (Details Narrative) - USD ($)	Jan. 14, 2021	Jan. 12, 2021	Dec. 21, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Preferred stock, par value				$ 0.001		$ 0.001
Number of shares issued, values
Securities Exchange Agreement [Member] | Medolife Rx, Inc. [Member]
Acquisition percentage	51.00%			51.00%
Share issued in exchange			9,000
Series B Convertible Preferred Stock [Member]
Preferred stock conversion description				the shares of Series B Convertible Preferred Stock are convertible into fifty-four percent (54%) of the issued and outstanding shares of the Company’s common stock on a fully converted basis
Conversion of shares into common stock		6,750
Compensation expense				$ 1,522,198
Series C Convertible Preferred Stock [Member]
Conversion of shares into common stock		6,750
Preferred stock, par value		$ 0.00001
Preferred stock, stated value per share		$ 100
Number of shares issued, shares	1,000
Number of shares issued, values	$ 169,133
Series C Convertible Preferred Stock [Member] | Trillium Partners LP [Member]
Number of shares issued, shares	500
Series C Convertible Preferred Stock [Member] | Sagittarii Holdings, Inc.[Member]
Number of shares issued, shares	500

SUMMARY OF RESTRICTED COMMON ST

SUMMARY OF RESTRICTED COMMON STOCK ACTIVITY (Details)	9 Months Ended
	Sep. 30, 2021USD ($)shares
Equity [Abstract]
Non-vested shares, Beginning balance | shares	3,250,000
Fair value of non-vested shares, Beginning balance | $	$ 431,411
Non-vested shares, Granted | shares
Fair value of non-vested shares, Granted | $
Non-vested shares, Vested | shares	(1,875,000)
Fair value of non-vested shares, Vested | $	$ (382,544)
Non-vested shares, Forfeited | shares
Fair value of non-vested shares, Forfeited | $
Non-vested shares, Ending balance | shares	1,375,000
Fair value of non-vested shares, Ending balance | $	$ 48,867

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Equity [Abstract]
Number of Options Outstanding, Beginning | shares	4,130,000
Options Outstanding, Weighted average exercise price, Beginning | $ / shares	$ 0.10
Options Outstanding, Contractual Life, Beginning	6 years
Number of Options Outstanding, Granted | shares
Options Outstanding, Granted, Weighted average exercise price | $ / shares
Number of Options Outstanding, Exercised | shares	(350,000)
Options Outstanding, Exercised, Weighted average exercise price | $ / shares
Number of Options Outstanding, Forfeited | shares	(3,005,000)
Options Outstanding, Forfeited, Weighted average exercise price | $ / shares
Number of Options Outstanding, Ending | shares	775,000
Options Outstanding, Weighted average exercise price, Ending | $ / shares	$ 0.10
Options Outstanding, Contractual Life, Ending	5 years 6 months
Number of Options Exercisable | shares	775,000
Options Exercisable, Weighted average exercise price | $ / shares	$ 0.10
Options Exercisable, Contractual Life	5 years 6 months

STOCKHOLDERS_ DEFICIT (Details

STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)	Apr. 30, 2020	Apr. 14, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2019	Apr. 14, 2021	Dec. 31, 2020
Subsidiary, Sale of Stock [Line Items]
Number of common stock shares issued, value
Number of shares issued for services, values			$ 2,126	$ 23,459	$ 1,316,884	972,038
Preferred stock, shares issued			2,500,000		2,500,000				2,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Number of restricted common stock vested					1,875,000
Shares issued for conversion of Convertible Notes			$ 236,482	$ 211,832	$ 1,543,570	211,832
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested					$ 382,544
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Restricted Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period							8,000,000
Number of restricted common stock vested					4,875,000		1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights							shares vested immediately, and the balance of 7,000,000 shares vest 625,000 shares per quarter over
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period							2 years 9 months 18 days
Share-based Payment Arrangement, Expense					$ 382,544	762,543
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount			48,867		48,867
Stock Options [Member]
Subsidiary, Sale of Stock [Line Items]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount			$ 22,000		22,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested					$ 34,905	$ 248,648
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	300,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.14
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 30,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	236.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.17%
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued, shares						5,018,519
Number of common stock shares issued, value						$ 5,000
Number of shares issued for services, shares			38,449	(500,117)	14,964,425	750,000
Number of shares issued for services, values			$ 38	$ 543	$ 14,964	$ 1,541
Shares issued for conversion of Convertible Notes			$ 15,765	$ 3,956	$ 89,137	$ 3,956
Common Stock [Member] | Convertible Notes Payable [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued for services, shares						1,127,522
Number of shares issued for services, values						$ 107,022
Preferred Stock [Member] | Series A Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued, shares
Number of common stock shares issued, value
Number of shares issued for services, shares
Number of shares issued for services, values		$ 465,000
Preferred stock, shares issued								2,500,000
Shares issued for conversion of Convertible Notes
Vendor [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued for services, shares					13,964,425	451,198
Number of shares issued for services, values					$ 1,246,934	$ 104,474
Employees and Officers [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued for services, shares					1,000,000
Number of shares issued for services, values					$ 69,950
Consultant [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued for services, shares						750,000
Number of shares issued for services, values						$ 209,495
Private Placement [Member] | Minimum [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued, price per share			$ 0.015		$ 0.015
Private Placement [Member] | Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued, price per share			0.02		$ 0.02
Common Stock Issued for Cash [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued, shares					44,750,000	407,408
Shares issued, price per share			$ 0.04	$ 0.26	$ 0.04	$ 0.26
Number of common stock shares issued, value					$ 1,985,000	$ 124,371
Common Stock Issued for Cash [Member] | Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued, shares					12,000,000
Conversion of Covertible Notes Payable [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued, shares					89,133,190

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Jan. 14, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty	$ 315,000	$ 180,000
Costs and Expenses, Related Party	198,800
Accounts receivable related party	198,800
Dr. Mikaelian [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Administrative expense	$ 628,742
Securities Exchange Agreement [Member] | Medolife Rx, Inc. [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquisition percentage	51.00%		51.00%
Securities Exchange Agreement [Member] | Dr. Mikaelian [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage	25.00%
Royalty	$ 35,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Nov. 12, 2021	Nov. 22, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	May 31, 2020	Apr. 30, 2020
Subsequent Event [Line Items]
Debt interest rate						10.90%	10.90%
Debt face amount			$ 225,759		$ 438,634
Debt Conversion, Description			It should be noted that contractually the limitations on the third-party notes (and the related warrant) limit the number of shares converted to either 4.99% or 9.99% of the then outstanding shares.
Number of shares reserved for future issuance	30,000,000
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Trillium Partners LP [Member]
Subsequent Event [Line Items]
Debt interest rate	12.00%
Debt face amount	$ 82,500
Proceeds from Issuance of Unsecured Debt	$ 75,000
Debt maturity date	Nov. 12, 2022
Debt Conversion, Description	The Investor is entitled to, at its option, convert all or any amount of the principal amount and any accrued but unpaid interest of the Investor Note into Common Stock, at any time, at a fixed conversion price for each share of Common Stock equal to $0.01 (as defined in the Note) of the Common Stock as reported on the OTC Marketplace exchange upon which the Company’s shares are traded during the twenty (20) consecutive Trading Day period immediately preceding (i) the applicable Effective Date; or (ii) the conversion date.
Warrants to purchase common stock	8,250,000
Common Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues				5,018,519
Common Stock [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues		7,128,571